Lefty ‘Consumer’ Watchdog Group Bought & Paid For By Big Pharma
The National Consumers League is America’s oldest consumer advocacy organization and a group trusted by the left, especially, to stand up for consumers’ interests.
But according to a review of its tax filings by the Washington Examiner, it has also become part of a web of astroturf groups shilling for the corporate interests of PhRMA, the massive drugmaker trade association that operates in Washington, DC, which donated close to $1 million to it just last year.
The organization’s 2024 tax form, which became available a few days ago, shows that the non-profit spent close to $600 million last year advocating for Big Pharma’s financial interests and policy agenda in Washington, DC, and state capitals across the country.
And a key way in which that advocacy was accomplished was through the National Consumers League, also known as NCL.
The Examiner reports that “PhRMA donated roughly $2 million to NCL between 2020 and 2024, including $875,000 in 2024 alone.”
During that time, NCL has hewed closely to PhRMA issue positions on matters including regulation of insurers that negotiate for lower drug prices for Americans (also known as PBMs), and the 340B drug discount program that disproportionately benefits red, rural America.
But a review of content historically featured on NCL’s website indicates that prior to taking PhRMA money, the group never criticized PBMs or 340B.
When asked for comment by the Examiner, NCL did not deny that their criticism of PBMs and 340B was related to the PhRMA funding, and they confirmed “that contributions from PhRMA support [the group’s] ‘healthcare work.’”
The Examiner has previously reported on apparent astroturf, “pay-to-play” advocacy efforts undertaken by PhRMA.
The Wall Street Journal also ran an exposé about PhRMA’s tactics in the nation’s capital, including what critics say looks like a “buying off” of supposed progressive “identity” groups like Black, Gifted & Whole– a group focused on “Black Queer men”– and MANA, A National Latina Organization.
NCL has also engaged on other issues where major industries have policy issues at stake, including higher interest rate short-term small dollar lending. Some credit unions support regulation of the annual percentage rate attached to such loans, but not the regulation of APRs on overdraft fees, which sometimes exceed more than 1000%.
Ironically, none other than Elizabeth Warren has recently taken to blasting credit unions for high overdraft fees.
The new report about PhRMA’s backing of NCL, coupled with these prior exposes, is a reminder that Health and Human Services Secretary Robert F. Kennedy, Jr., will have his work cut out for him diminishing Big Pharma’s influence over national health care policy.
Tyler Durden
Fri, 12/12/2025 – 19:15